SCHEMBL989186

SCHEMBL989186

CC(C)Cn1c(N)nc2ccc(C(=O)C(=O)c3ccccc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 7/20 0.48
LMNA P02545 2/20 0.47
PI4KB Q9UBF8 1/20 0.46
MAPK14 Q16539 1/20 0.46
KDM4E B2RXH2 1/20 0.43
DYRK3 O43781 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
ERBB2 P04626 1/20 0.42
PIM1 P11309 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT4 P35916 1/20 0.42
FRK P42685 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1D P48730 1/20 0.42
LIMK1 P53667 1/20 0.42
MAP4K2 Q12851 1/20 0.42
CAMK2B Q13554 1/20 0.42
CAMK2G Q13555 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989513 0.81 PI4KB (0.46) ACSS2PI4KBKDM4EF2RMEN1
SCHEMBL991367 0.81 PI4KB (0.46) ACSS2PI4KBKDM4EF2RMEN1
SCHEMBL989515 0.81 PI4KB (0.46) ACSS2PI4KBKDM4EF2RMEN1
SCHEMBL5984668 0.80 ACSS2 (0.45) ACSS2PI4KBF2RMEN1NPC1
SCHEMBL4837467 0.77 PI4KB (0.74) PI4KBMAPK14ERBB2PIM1FGFR1
SCHEMBL989222 0.75 HTT (0.67) LMNAKDM4EMEN1NPC1RAB9A
SCHEMBL990617 0.75 MAPK14 (0.43) ACSS2LMNAMAPK14KDM4EDYRK3
SCHEMBL989394 0.73 DYRK3 (0.46) MAPK14DYRK3PRKD3MAP4K4ERBB2
SCHEMBL989352 0.73 DYRK3 (0.43) ACSS2LMNAMAPK14KDM4EDYRK3
SCHEMBL11008032 0.73 PI4KB (0.50) LMNAPI4KBKDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 ACSS2 2448/4885LMNA 3587/4885PI4KB 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.